Evidence map›Paper›PMID 41307702›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Contribution of quantitative I-123-ioflupane SPECT/CT to the differential diagnosis of dementia with lewy bodies.

George Karun Kurian, Paolo Salvioni Chiabotti, Caroline Hall, Noemie Lejay, Jérémy Perriraz, Olivier Rouaud, Adrien Depeursinge, Marie Nicod Lalonde, Niklaus Schaefer, Gilles Allali and 2 more

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

George Karun KurianDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Paolo Salvioni ChiabottiLeenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Caroline HallLeenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Noemie LejayLeenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Jérémy PerrirazDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Olivier RouaudLeenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Adrien DepeursingeDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Marie Nicod LalondeDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Niklaus SchaeferDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Gilles AllaliLeenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
John O PriorDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. john.prior@chuv.ch.ORCID 0000-0003-1429-1374
Mario JreigeDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeQuantification of I-123-ioflupane uptake using modern SPECT/CT improves diagnostic accuracy for disorders affecting the nigrostriatal pathway. This study assessed whether absolute and relative standardized uptake values (SUV) could distinguish dementia with Lewy bodies (DLB) from non-DLB in patients with suspected DLB and explored associations with core clinical features, including visual hallucinations (VH) and REM sleep behavior disorder (RBD).

methodsSeventy-four patients (mean age 71.5 ± 9.26 years; 39% female) were retrospectively included. All underwent I-123-ioflupane SPECT/CT imaging with both iterative (Flash 3D) and quantitative reconstructions. SUVmax, SUVmean, and relative SUV (rSUV) values were extracted for the caudate, putamen, and striatum. Uptake metrics were compared between DLB and non-DLB groups and analyzed in relation to clinical features, including visual hallucinations (VH) and REM sleep behavior disorder (RBD).

resultsVisual assessment classified 28/74 scans (38%) as abnormal (sensitivity 90%, specificity 80%, AUC 0.846). Quantitative SUVmax in the striatum and putamen showed the highest diagnostic performance (AUC up to 0.83). Striatal SUVmax remained an independent predictor of DLB in multivariable analysis (OR = 0.58, p = 0.003). Patients with VH had significantly lower striatal SUVmax than those without (p = 0.004), with an optimal cutoff of ≤ 6.0 g/mL (AUC = 0.70, sensitivity 64.3%, specificity 80.4%). No significant differences were observed for RBD.

conclusionQuantitative I-123-ioflupane uptake assessment using SUV measures offers clinically relevant diagnostic value for differentiating DLB from other neurodegenerative diseases. It also helps in identifying patients with visual hallucinations, supporting the broader integration of SUV-based dopaminergic imaging into clinical workflows.

Indexed as

Lewy Body DiseaseNortropanesSingle Photon Emission Computed Tomography Computed TomographyAgedAged, 80 and overDiagnosis, DifferentialFemaleHallucinationsHumansMaleMiddle AgedRetrospective StudiesioflupaneNortropanesDementia with lewy bodiesDopamine transporter imagingI-123-ioflupaneQuantitative imagingSPECT/CTSUV (standardized uptake value)Visual hallucinations

Identifiers

PMID41307702
PMCPMC12920399

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.